|
medpundit |
||
 |
 |
|
Thursday, December 23, 2004The Food and Drug Administration (FDA) is advising health care professionals about a new warning for Strattera, a drug approved for attention deficit hyperactivity disorder (ADHD) in adults and children. The labeling is being updated with a bolded warning about the potential for severe liver injury following two reports (a teenager and an adult) in patients who had been treated with Strattera for several months, both of whom recovered. ...The labeling warns that severe liver injury may progress to liver failure resulting in death or the need for a liver transplant in a small percentage of patients. The labeling also notes that the number of actual cases of severe liver injury is unknown because of under-reporting of post-marketing adverse events. posted by Sydney on 12/23/2004 08:02:00 AM 2 comments 2 Comments:This comment has been removed by a blog administrator.
By
Hey there,
By |
|
